Drug
Brodalumab
Brodalumab: highest development phase Post-Market, developed by Bausch Health, Kyowa Kirin. 2 trial records tracked on RxWires.
- Highest phase
- Post-Market
- Developer
- Bausch Health, Kyowa Kirin
Trials
| Drug | Phase | Indication |
|---|---|---|
| Brodalumab NCT03240809 | Post-Market | Psoriasis |
| Brodalumab 210mg SC NCT04183881 | Post-Market | Psoriasis Vulgaris |
Latest
No recent events.
Follow Brodalumab on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.